血管肉腫治療の世界市場-2023年～2030年

市場概要

世界の血管肉腫治療市場は、2022年に2億5,310万米ドルに達し、2023～2030年の予測期間中にCAGR 6.4％で成長し、2030年には4億1,230万米ドルに達すると予測されています。

血管肉腫は体のどこにでも発生する可能性があるが、皮膚、乳房、肝臓、脾臓に発生することが多いです。世界の血管肉腫治療市場は、標的療法の採用により近年著しい成長を遂げています。例えば、血管肉腫で制御されている血管内皮増殖因子は、パゾパニブやレゴラフェニブなどのチロシンキナーゼ阻害剤によって標的とすることができます。

さらに、臨床試験の増加、共同研究の増加、研究開発などの重要な成長要因が将来の市場開拓をもたらします。米国やカナダのような国々における技術進歩の大幅な上昇により、市場は北米地域からの需要が増加しています。Amgen Inc.、Eli Lilly, and Company、Genentech Inc.などの主要企業が市場で積極的に活動しています。

ダイナミクス

血管肉腫治療の研究開発の増加

世界の血管肉腫治療市場は、様々な最近の研究開発により大きな成長を遂げています。血管肉腫は通常、病歴や臨床所見、画像所見に基づいて診断されます。また、血管肉腫の治療における先進的な研究開発は、市場の成長を加速させるのに役立っています。

例えば、2022年11月に発表された「Cutaneous angiosarcoma treated with taxane-based chemoradiotherapy（タキサン系化学放射線療法で治療される皮膚血管肉腫）」と題する論文によると、臨床研究によって、皮膚血管肉腫の治療の第一選択化学療法として、パクリタキセルやドセタキセルなどのタキサン系薬剤の重要性が示唆されています。さらに、タキサン系薬剤を用いた化学放射線療法は、手術や放射線療法と比較して高い奏効率を達成し、全生存期間を有意に改善しました。このように、上記のような要因が予測期間における市場成長を後押ししています。

血管肉腫治療の技術的進歩の高まり

血管肉腫は血管やリンパ管の内膜に発生するため、主要企業の技術開発が市場成長の原動力となっています。皮膚は最も罹患率の高い部位であり、症例の約57.21%が皮膚血管肉腫です。このような効果的な進歩は、研究の発見を新しい治療法に変え、血管肉腫を患う何十億もの人々のケアを改善するのに役立っています。

例えば、Springer Journal誌が2023年4月に発表した論文では、空間トランスクリプトミクスがアジアの頭頸部血管肉腫の位相幾何学的免疫ランドスケープを明らかにしたと述べています。この論文は、10x Genomics Visiumプラットフォームを用いた空間トランスクリプトミクス・プロファイリングを含み、血管肉腫の位相幾何学的腫瘍免疫ランドスケープを明らかにすることにより、UVシグネチャーとHHV-7の有無によって特徴づけられる代表的な症例で実施されます。このように、上記の要因により、市場は予測期間中に拡大すると予想されます。

リンパ管肉腫に伴う合併症が世界市場の成長を妨げると予想される

リンパ管肉腫の合併症には、蜂巣炎、筋骨格系の痛み、心理的ストレス、悪性腫瘍のリスク増加などがあります。蜂窩織炎は通常、抗生物質の経口投与で発症し、蜂窩織炎は皮膚の下にある真皮や皮下組織の細菌感染であり、リンパ管肉腫に関連する最も一般的な合併症です。したがって、上記の要因により、予測期間中、市場は低迷すると予想されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 血管肉腫治療の研究開発の増加
    • 血管肉腫治療のための技術進歩の高まり
  • 抑制要因
    • リンパ管肉腫に伴う合併症
  • 機会
    • 血管肉腫治療の新興市場
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• アンメットニーズ
• 規制分析

第6章 COVID-19分析

第7章 タイプ別

• 血管肉腫
• リンパ管肉腫
• 実質血管肉腫

第8章 治療法別

• 手術
• 放射線療法
• 化学療法
• 標的療法
• 免疫療法
• その他

第9章 エンドユーザー別

• 病院
• クリニック
• 外来手術センター
• その他

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
    • アルゼンチン
    • その他南米
• アジア太平洋
  • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
• 中東・アフリカ

第11章 競合情勢

• 競合シナリオ
• 製品ベンチマーク
• 企業シェア分析
• 主な発展と戦略

第12章 企業プロファイル

• Novartis AG
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な動向
• Bayer AG
• Sanofi
• Amgen Inc.
• Eli Lilly and Company
• Genentech Inc.
• Janssen Pharmaceuticals
• AbbVie Inc.
• Bausch Health
• GlaxoSmithKline Plc.

第13章 付録

Market Overview

Global Angiosarcoma Treatment Market reached US$ 253.1 million in 2022 and is expected to reach US$ 412.3 million by 2030 growing with a CAGR of 6.4% during the forecast period 2023-2030.

Angiosarcoma can develop anywhere in the body but most often occur in the skin, breast, liver, and spleen. The global angiosarcoma treatment market has witnessed significant growth in recent years due to the adoption of targeted therapies. For instance, vascular endothelial growth factor which is regulated in angiosarcoma can be targeted by tyrosine kinase inhibitors such as pazopanib and regorafenib.

Furthermore, significant growth drivers such as increasing clinical trials, increasing collaborations, and research and developments give rise to future market growth. Due to the massive rise in technological advancements in countries like the U.S. and Canada, the market is experiencing a rise in demand from North American regions. Significant key players like Amgen Inc., Eli Lilly, and Company, Genentech Inc., and others are actively operating in the market.

Dynamics

Increasing Research and Developments for Angiosarcoma Treatment

The global angiosarcoma treatment market has witnessed significant growth due to various recent research and developments. Angiosarcoma is usually diagnosed on the basis of medical history and clinical and imaging findings. Also, advanced research and developments in treating angiosarcoma help to accelerate market growth.

For instance, according an article entitled Cutaneous angiosarcoma treated with taxane-based chemoradiotherapy published on November 2022 states that clinical studies have suggested the importance of taxane-derived agents such as paclitaxel and docetaxel as first-line chemotherapy for treatment of cutaneous angiosarcoma. In addition, chemoradiotherapy with taxanes achieved a high response rate with significant improvement in overall survival compared with surgery or radiotherapy. Thus, the above factors help to boost the market growth in the forecast period.

Rising Technological Advancements for Angiosarcoma Treatment

Angiosarcoma develops in the inner lining of blood vessels and lymph vessels and the major advancements from major companies help to drive market growth. Skin is the most affected area with approximately 57.21% of cases being cutaneous angiosarcoma. These effective advancements help to transform research discoveries into new treatments and improve care for billions of people with angiosarcoma.

For instance, Springer Journal published an article in April 2023, states that spatial transcriptomics reveals topological immune landscapes of Asian head and neck angiosarcoma. It involves spatial transcriptomic profiling using the 10x Genomics Visium platform that is performed on representative cases characterized by the presence or absence of UV signatures and HHV-7 by revealing the topological tumor immune landscape of angiosarcoma. Thus, owing to the above factors the market is expected to boost over the forecast period.

Complications Associated with Lymphangiosarcoma is Expected to Hamper Global Market Growth

Complications of lymphangiosarcoma include cellulitis, musculoskeletal pain, psychological stress, and an increased risk of malignancy. Cellulitis usually occurs with oral antibiotics and cellulitis is a bacterial infection of the dermis and subcutaneous tissues underneath the skin and is the most common complication associated with lymphangiosarcoma. Thus, owing to the above factors the market is expected to hamper over the forecast period.

Segment Analysis

The global angiosarcoma treatment market is segmented based on type, treatment, end users, and region.

Immunotherapy from the Treatment Segment Accounted for Approximately 38.5% of the Global Angiosarcoma Treatment Market Share

The rising clinical trials of angiosarcoma globally have contributed to the growing demand for angiosarcoma treatment. Immunotherapy includes drugs that activate the immune system that modify the immune system cells to target tumor cells and monoclonal antibodies, checkpoint inhibitors, and vaccines are the common types of immunotherapies.

For instance, according to clinicalTrials.gov, on April 5, 2023, M.D. Anderson Cancer Center conducted a clinical trial on Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma. The main aim is to determine the safety, toxicity, and feasibility of delivering autologous dendritic cells (DCs) loaded with tumor lysate plus mRNA to patients with cutaneous head & neck angiosarcoma as adjuvant therapy. Thus, the above factors help to acceleratethe market growth.

Geographical Penetration

North America Accounted for Approximately 38.4% of the Market Share in 2022

North America has maintained a significant proportion of the angiosarcoma market in recent years, and this trend is anticipated to continue throughout the forecast period due to the factors such as an increase in healthcare expenditures, increasing research and developments, and technological advancements in angiosarcoma treatment.

For instance, according to the National Health Expenditure Account (NHEA), the total annual healthcare expenditure in the United States is increased by 2.7% to $4.3 trillion. Physician spending grew by an average of 3.8% per year while hospital services (4.5%) and clinical services (6.6%) had higher growth rates.

Competitive Landscape

The major global players in the market include: Novartis AG,Bayer AG,Sanofi,Amgen Inc.,Eli Lilly and Company,Genentech Inc.,Janssen Pharmaceuticals, AbbVie Inc, Bausch Health, GlaxoSmithKline Plc.among others.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the angiosarcoma treatment market. During the height of the pandemic, many healthcare systems were overwhelmed, and non-urgent medical procedures and screenings were postponed or canceled. This led to delays in angiosarcoma treatment research. Clinical trials are vital for developing new treatments and improving outcomes in the angiosarcoma treatment market.

However, the pandemic disrupted the conduct of clinical trials, with many sites temporarily halting enrollment or modifying protocols to prioritize patient safety. This has led to delays in the completion of trials and the availability of new therapies. Moreover, the focus of research and development efforts shifted during the pandemic, with a significant emphasis on developing vaccines and treatments for COVID-19. Therefore, owing to the above factors, the angiosarcoma treatment market is expected to be moderately affected over the forecast period.

By Type

• Hemangiosarcoma
• Lymphangiosarcoma
• Parenchymal Angiosarcoma

By Treatment

• Surgery
• Radiotherapy
• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Others

By End Users

• Hospitals
• Clinics
• Ambulatory Surgical Centers
• Others

By Region

• North America

U.S.

Canada

Mexico

• Europe

Germany

U.K.

France

Italy

Spain

Rest of Europe

• South America

Brazil

Argentina

Rest of South America

• Asia-Pacific

China

India

Japan

Australia

Rest of Asia-Pacific

• Middle East and Africa

Key Developments

• In September 2020, during the ESMO Virtual Congress, data from the sarcoma cohort of the phase 2 basket study is presented and showed that pembrolizumab monotherapy prolonged progression-free survival (PFS) in selected rare sarcoma subtypes including epithelioid sarcoma, angiosarcoma, and chondrosarcoma.
• In December 2020, a new study led by clinician-scientists from the National Cancer Centre Singapore (NCCS) with collaborators from research institutions worldwide found that angiosarcomas have unique genomic and immune profiles which allow them to be classified into three different subtypes. With this new classification, patients can be treated using a personalized-medicine approach.

Why Purchase the Report?

• To visualize the global angiosarcoma treatment market segmentation based on the type, treatment, end users, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of globalangiosarcoma treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global angiosarcoma treatment market report would provide approximately 69 tables, 70 figures, and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Treatment
• 3.3. Snippet by End Users
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing research and developments for angiosarcoma treatment
    • 4.1.1.2. Rising technological advancements for angiosarcoma treatment
  • 4.1.2. Restraints
    • 4.1.2.1. Complications associated with lymphangiosarcoma
  • 4.1.3. Opportunity
    • 4.1.3.1. Emerging markets of angiosarcoma treatments
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Unmet Needs
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers' Strategic Initiatives
• 6.6. Conclusion

7. By Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 7.1.2. Market Attractiveness Index, By Type
• 7.2. Hemangiosarcoma*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Lymphangiosarcoma
• 7.4. Parenchymal Angiosarcoma

8. By Treatment

• 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
• 8.1.2. Market Attractiveness Index, By Treatment
• 8.2. Surgery
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Radiotherapy
• 8.4. Chemotherapy
• 8.5. Targeted Therapy
• 8.6. Immunotherapy
• 8.7. Others

9. By End Users

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
  • 9.1.2. Market Attractiveness Index, By End Users
• 9.2. Hospitals*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Clinics
• 9.4. Ambulatory Surgical Centers
• 9.5. Others

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
  • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
  • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. U.K.
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
  • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  • 10.4.7. Brazil
    • 10.4.7.1. Argentina
    • 10.4.7.2. Rest of South America
• 10.5. Asia Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%),ByTreatment
  • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
  • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  • 10.5.7. China
    • 10.5.7.1. India
    • 10.5.7.2. Japan
    • 10.5.7.3. Australia
    • 10.5.7.4. Rest of Asia Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Product Benchmarking
• 11.3. Company Share Analysis
• 11.4. Key Developments and Strategies

12. Company Profiles

• 12.1. Novartis AG*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Bayer AG
• 12.3. Sanofi
• 12.4. Amgen Inc.
• 12.5. Eli Lilly and Company
• 12.6. Genentech Inc.
• 12.7. Janssen Pharmaceuticals
• 12.8. AbbVie Inc.
• 12.9. Bausch Health
• 12.10. GlaxoSmithKline Plc.

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us